Taiwan Liposome Co (台灣微脂體) is expected to raise NT$591.36 million (US$20.31 million) from its initial public offering (IPO) on Friday next week, with the firm planning to use the proceeds to improve its gross margin and strengthen its bottom line.
The biopharmaceutical company, headquartered in Taipei’s Nangang Software Park (南港軟體園區), plans to issue 4.62 million new shares on its the GRETAI Securities Market debut and has tentatively set the IPO price at NT$128, the company said.
On Monday, Taiwan Liposome began book building for institutional investors after receiving regulatory approval. The book building, whereby institutional investors make bids for the stock on offer, ends on Thurday, the company said.
Taiwan Liposome currently trades on the smaller Emerging Stock Market, a preparatory board for the nation’s two main bourses. Its shares closed 1.64 percent higher yesterday at NT$279.50, rising 288.9 percent so far this year, according to stock exchange data.
The company reported a net income of NT$24.3 million, or earnings per share of NT$0.62, in the third quarter, after posting a net loss of NT$40.69 million, or a net loss per share of NT$1.04 per share, in the first half of the year.
In the first three quarters of the year, Taiwan Liposome posted a net loss of NT$16.34 million, or loss per share of NT$0.42, much lower than a net loss of NT$137.43 million, or NT$5.11 per share, a year earlier, company data showed.
During the first 11 months of the year, sales surged 210.7 percent to NT$233.195 million from NT$75.048 million a year ago, the company said on Monday.
Analysts say the company is likely to swing into profit next year on the back of certain milestone payments and royalties on product sales. Taiwan Liposome reported a net loss of NT$216.99 million last year, NT$190.21 million in 2010 and NT$184.07 million in 2009.
Established in 1997, Taiwan Liposome focuses on the research and development of pharmaceutical products based on its proprietary drug delivery technologies.
“Traditionally, drugs are transmitted via blood, and the amount of drugs that can reach infected organs is little,” Taiwan Liposome president George Yeh (葉志鴻) said at a pre-IPO conference for investors on Nov. 28.
“We use lipid-based formulation that delivers the drug to infected body parts and releases the drug there, creating better efficacy and lower toxicity for the drugs,” Yeh said.
Lipid-based formulations can also be used to control the amount of drugs released in a given period of time, prolonging the product lifecycle of drugs.
In the past few years, Taiwan Liposome has developed drugs used to treat breast cancer and ovarian cancer, such as Lipo-Dox and Doxisome, as well as ProFlow, a drug used to treat peripheral vascular disease. The company is expected to invest NT$1.15 billion into new drug development from this year through 2016.
WASHINGTON’S INCENTIVES: The CHIPS Act set aside US$39 billion in direct grants to persuade the world’s top semiconductor companies to make chips on US soil The US plans to award more than US$6 billion to Samsung Electronics Co, helping the chipmaker expand beyond a project in Texas it has already announced, people familiar with the matter said. The money from the 2022 CHIPS and Science Act would be one of several major awards that the US Department of Commerce is expected to announce in the coming weeks, including a grant of more than US$5 billion to Samsung’s rival, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), people familiar with the plans said. The people spoke on condition of anonymity in advance of the official announcements. The federal funding for
HIGH DEMAND: The firm has strong capabilities of providing key components including liquid cooling technology needed for AI servers, chairman Young Liu said Hon Hai Precision Industry Co (鴻海精密) yesterday revised its revenue outlook for this year to “significant” growth from a “neutral” view forecast five months ago, due to strong demand for artificial intelligence (AI) servers from cloud service providers. Hon Hai, a major assembler of iPhones that is also known as Foxconn, expects AI server revenues to soar more than 40 percent annually this year, chairman Young Liu (劉揚偉) told investors. The robust growth would uplift revenue contribution from AI servers to 40 percent of the company’s overall server revenue this year, from 30 percent last year, Liu said. In the three-year period
LONG HAUL: Largan Energy Materials’ TNO-based lithium-ion batteries are expected to charge in five minutes and last about 20 years, far surpassing conventional technology Largan Precision Co (大立光) has formed a joint venture with the Industrial Technology Research Institute (ITRI, 工研院) to produce fast-charging, long-life lithium-ion batteries for electric vehicles, mobile electronics and electric storage units, the camera lens supplier for Apple Inc’s iPhones said yesterday. Largan Energy Materials Co (萬溢能源材料), established in January, is developing high-energy, fast-charging, long-life lithium-ion batteries using titanium niobium oxide (TNO) anodes, it said. TNO-based batteries can be fully charged in five minutes and have a lifespan of 20 years, a major advantage over the two to four hours of charging time needed for conventional graphite-anode-based batteries, Largan said in a
Taiwan is one of the first countries to benefit from the artificial intelligence (AI) boom, but because that is largely down to a single company it also represents a risk, former Google Taiwan managing director Chien Lee-feng (簡立峰) said at an AI forum in Taipei yesterday. Speaking at the forum on how generative AI can generate possibilities for all walks of life, Chien said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) — currently among the world’s 10 most-valuable companies due to continued optimism about AI — ensures Taiwan is one of the economies to benefit most from AI. “This is because AI is